Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMRX NASDAQ:MOLN NASDAQ:THTX NASDAQ:XLO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMRXImmuneering$8.14+15.5%$4.37$1.10▼$9.37$293.07M0.431.04 million shs3.32 million shsMOLNMolecular Partners$3.72+0.0%$3.70$3.36▼$7.60$150.19M1.15,009 shs2,889 shsTHTXTheratechnologies$3.27$3.20$1.12▼$3.28$150.35M0.51356,243 shs268,889 shsXLOXilio Therapeutics$0.74-1.2%$0.70$0.62▼$1.70$38.87M-0.14865,078 shs978,773 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMRXImmuneering+15.46%+51.58%+153.58%+315.31%+581.17%MOLNMolecular Partners-1.43%-0.13%+1.50%-4.59%-33.67%THTXTheratechnologies0.00%+0.93%+2.19%+29.25%+173.64%XLOXilio Therapeutics-1.17%+2.40%+8.97%+8.43%-13.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMRXImmuneering$8.14+15.5%$4.37$1.10▼$9.37$293.07M0.431.04 million shs3.32 million shsMOLNMolecular Partners$3.72+0.0%$3.70$3.36▼$7.60$150.19M1.15,009 shs2,889 shsTHTXTheratechnologies$3.27$3.20$1.12▼$3.28$150.35M0.51356,243 shs268,889 shsXLOXilio Therapeutics$0.74-1.2%$0.70$0.62▼$1.70$38.87M-0.14865,078 shs978,773 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMRXImmuneering+15.46%+51.58%+153.58%+315.31%+581.17%MOLNMolecular Partners-1.43%-0.13%+1.50%-4.59%-33.67%THTXTheratechnologies0.00%+0.93%+2.19%+29.25%+173.64%XLOXilio Therapeutics-1.17%+2.40%+8.97%+8.43%-13.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMRXImmuneering 2.60Moderate Buy$13.0059.71% UpsideMOLNMolecular Partners 3.00Buy$8.00115.00% UpsideTHTXTheratechnologies 3.00BuyN/AN/AXLOXilio Therapeutics 3.33Buy$3.00304.75% UpsideCurrent Analyst Ratings BreakdownLatest XLO, IMRX, MOLN, and THTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025MOLNMolecular PartnersJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$4.50 ➝ $4.008/26/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.008/14/2025IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.008/6/2025XLOXilio TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/6/2025XLOXilio TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$2.007/3/2025THTXTheratechnologiesJones TradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/18/2025IMRXImmuneeringMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$8.00 ➝ $10.006/18/2025IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.006/18/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.00(Data available from 9/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMRXImmuneering$320K1,057.44N/AN/A$1.33 per share6.12MOLNMolecular Partners$5.65M26.59N/AN/A$3.99 per share0.93THTXTheratechnologies$85.87M1.75N/AN/A($0.55) per share-5.95XLOXilio Therapeutics$6.34M6.06N/AN/A$0.40 per share1.85Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMRXImmuneering-$61.04M-$1.89N/AN/AN/AN/A-146.28%-117.22%11/12/2025 (Estimated)MOLNMolecular Partners-$61.39M-$2.08N/AN/AN/AN/A-50.66%-45.13%10/30/2025 (Estimated)THTXTheratechnologies-$8.31M-$0.19N/A46.71N/A-10.85%N/A-9.83%10/9/2025 (Estimated)XLOXilio Therapeutics-$58.24M-$0.76N/AN/AN/A-374.79%-399.15%-58.68%11/6/2025 (Estimated)Latest XLO, IMRX, MOLN, and THTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/25/2025H1 2025MOLNMolecular Partners-$0.53-$0.67-$0.14-$0.67N/AN/A8/14/2025Q2 2025XLOXilio Therapeutics-$0.08-$0.16-$0.08-$0.16$8.21 million$8.21 million8/13/2025Q2 2025IMRXImmuneering-$0.40-$0.40N/A-$0.40N/AN/A7/9/2025Q2 2025THTXTheratechnologies-$0.01-$0.09-$0.08-$0.09$24.30 million$17.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMRXImmuneeringN/AN/AN/AN/AN/AMOLNMolecular PartnersN/AN/AN/AN/AN/ATHTXTheratechnologiesN/AN/AN/AN/AN/AXLOXilio TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMRXImmuneeringN/A3.703.70MOLNMolecular PartnersN/A9.359.35THTXTheratechnologiesN/A0.840.65XLOXilio TherapeuticsN/A2.322.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMRXImmuneering67.65%MOLNMolecular Partners26.55%THTXTheratechnologiesN/AXLOXilio Therapeutics54.29%Insider OwnershipCompanyInsider OwnershipIMRXImmuneering22.90%MOLNMolecular Partners5.93%THTXTheratechnologiesN/AXLOXilio Therapeutics5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMRXImmuneering6041.57 million28.00 millionNot OptionableMOLNMolecular Partners18040.38 million37.98 millionNot OptionableTHTXTheratechnologies14045.98 millionN/AOptionableXLOXilio Therapeutics7051.83 million49.13 millionNot OptionableXLO, IMRX, MOLN, and THTX HeadlinesRecent News About These CompaniesXilio Therapeutics sees cash runway into 1Q27September 9 at 11:39 AM | msn.comXilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under ...September 9 at 11:39 AM | finance.yahoo.comXilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with GileadSeptember 9 at 7:30 AM | globenewswire.comXilio Therapeutics (XLO) Has a New Rating from Leerink PartnersAugust 29, 2025 | theglobeandmail.comXilio Therapeutics Faces Nasdaq Equity Compliance ChallengeAugust 28, 2025 | tipranks.comXLO | Xilio Therapeutics Inc. Annual Cash Flow Statement | MarketWatchAugust 16, 2025 | marketwatch.comXilio Therapeutics reports Q2 EPS (16c) vs (24c) last yearAugust 15, 2025 | msn.comXilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial ResultsAugust 15, 2025 | taiwannews.com.twTXilio Revenue Jumps 246 Percent in Q2August 15, 2025 | aol.comAXilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue EstimatesAugust 14, 2025 | zacks.comXilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial ResultsAugust 14, 2025 | globenewswire.comLeerink Partners Initiates Coverage of Xilio Therapeutics (XLO) with Outperform RecommendationAugust 7, 2025 | msn.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 1, 2025 | globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - MorningstarJuly 3, 2025 | morningstar.comMXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 2, 2025 | globenewswire.comJames Samuel Shannon Acquires 25,000 Shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) StockJune 19, 2025 | insidertrades.comXilio Therapeutics expands board, elects new directorJune 12, 2025 | investing.comXilio Therapeutics Appoints Akintunde Bello, Ph.D., to Board of DirectorsJune 10, 2025 | quiverquant.comQXilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of DirectorsJune 10, 2025 | globenewswire.comXilio Therapeutics Announces Closing of $50.0 Million Public OfferingJune 5, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXLO, IMRX, MOLN, and THTX Company DescriptionsImmuneering NASDAQ:IMRX$8.14 +1.09 (+15.46%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$8.53 +0.39 (+4.79%) As of 09/10/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.Molecular Partners NASDAQ:MOLN$3.72 +0.00 (+0.03%) Closing price 09/10/2025 03:55 PM EasternExtended Trading$3.75 +0.03 (+0.75%) As of 09/10/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.Theratechnologies NASDAQ:THTX$3.27 0.00 (0.00%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$3.28 +0.01 (+0.31%) As of 09/10/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.Xilio Therapeutics NASDAQ:XLO$0.74 -0.01 (-1.17%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$0.74 0.00 (-0.43%) As of 09/10/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Part of the Club: Robinhood & AppLovin Soar on S&P 500 Inclusion Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
